OBJECTIVES:  In recent years newer mutation-specific and targeted therapies have become available for the management of ovarian cancer (OC). However, there are limited data documenting recent treatment patterns among women with OC. METHODS:  A retrospective observational study was conducted using the Humedica EHR database (2007-2014). Women diagnosed with OC (ICD-9-CM code 183.0x), enrolled in an integrated delivery network and receiving chemotherapy or cancer directed surgery were included in the study. Patients were followed from index OC diagnosis date until end of database, death date or database activity end date, whichever occurred earlier. Study measures assessed included patient demographic and clinical characteristics and post-diagnosis treatment patterns including treatments received (surgery, chemotherapy, targeted and radiation therapy), treatment sequence, line of therapy. All analyses were descriptive in nature. RESULTS:  The study cohort included 2,158 patients with an average age of 62 (SD: 13) years and average post-diagnosis follow-up of 29 months in the database. Post diagnosis OC-related treatments included: chemotherapy (67%), surgery (65%), radiation therapy (10%) and targeted therapy (bevacizumab 9% [approved in the US for platinum-resistant recurrent OC in combination with paclitaxel, pegylated liposomal doxorubicin or topotecan]). Among patients initiating first-line therapy, carboplatin alone or in combination with other agents accounted for ~63% of first-line regimens. Commonly observed first-line non-platinum based therapies included paclitaxel (5%), doxorubicin (3%) and gemcitabine (2%). Among first-line therapy initiators 42% had evidence of second-line therapy in the database. Similarly, among patients with second-line therapy, 56% had evidence for a third-line therapy in the database with doxorubicin (20%) and carboplatin+paclitaxel (15%) being the commonly observed third-line therapies. CONCLUSIONS:  This study provides recent treatment patterns data among women with OC in the US. With newer therapies being developed for OC, findings from this study can serve as inputs in the development of budget impact models comparing new and existing treatments.